Vistin Pharma ASA: Second quarter and YTD 2025 financial results

What are the key drivers behind the reported Q2 earnings and how sustainable are they? How does Vistin Pharma's Q2 revenue growth compare to its historical performance and analyst expectations? How might the Q2 results affect the short‑term technical momentum and trading volume of VIST? Are there any changes in the company's guidance or dividend policy that could affect valuation? How does the current valuation multiple (e.g., P/E, EV/EBITDA) compare to peers in the pharmaceutical sector? What macro or regulatory factors could influence Vistin Pharma's performance in the coming quarters? Is there any indication of changes in the company's capital allocation strategy, such as M&A or share buybacks? What are the potential risks or upside catalysts that could cause the stock to deviate from consensus forecasts? How does the sentiment score of 10 reflect market perception, and could it lead to a price overreaction? What is the outlook for the company's pipeline and its potential impact on future cash flows?